All In Biotech

Drug Trial Radar · NCT03164616

Study of Durvalumab + Tremelimumab With Chemotherapy or Durvalumab With Chemotherapy or Chemotherapy Alone for Patients With Lung Cancer (POSEIDON).

A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)

Last checked: Nov 20, 2026Latest source record: Mar 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,186 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,186

Actual

Start

Jun 1, 2017

Primary completion

Mar 12, 2021

Study completion Nov 15, 2027

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
May 23, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 130 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, open-label, multi-center, global, Phase III study to determine the efficacy and safety of durvalumab + tremelimumab combination therapy + Standard of care (SoC) chemotherapy or durvalumab monotherapy + SoC chemotherapy versus SoC chemotherapy alone as first line treatment in patients with metastatic non small-cell lung cancer (NSCLC) with tumors that lack activating epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) fusions.

Conditions

  • Non Small Cell Lung Cancer NSCLC

Interventions

  • DurvalumabDrug

    IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria

  • TremelimumabDrug

    IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.

  • Abraxane + carboplatinDrug

    Standard of care chemotherapy (squamous and non-squamous patients): Abraxane 100 mg/m2 on Days 1, 8, and 15 of each 21-day cycle. Carboplatin Area under the plasma drug concentration-time curve (AUC) 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).

  • Gemcitabine + cisplatinDrug

    Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).

  • Gemcitabine + carboplatinDrug

    Standard of care chemotherapy (squamous patients only): Gemcitabine 1000 or 1250 mg/m2 via IV infusion on Days 1 and 8 of each 21-day cycle + carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3).

  • Pemetrexed + carboplatinDrug

    Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and carboplatin AUC 5 or 6 via IV infusion on Day 1 of each 21-day cycle for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.

  • Pemetrexed + cisplatinDrug

    Standard of care chemotherapy (non-squamous patients only): Pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 via IV infusion on Day 1 of each 21-day cycle, for 4 to 6 cycles (ie, 4 cycles for Treatment Arms 1 and 2 and 4 to 6 cycles for Treatment Arm 3); then continue pemetrexed 500 mg/m2 maintenance \[i.e., q4w for Treatment Arms 1 and 2. For Treatment Arm 3, Pemetrexed maintenance therapy can be given either q3w or q4w (dependent on Investigator decision and local standards)\] until objective disease progression.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-Free Survival (PFS); D + SoC Compared With SoC AloneTime frame: Tumor scans performed at baseline, Week 6, Week 12 and then every 8 weeks relative to date of randomization until radiological progression. Assessed until global cohort DCO of 24 July 2019 (maximum of approximately 25 months).
  2. Overall Survival (OS); D + SoC Compared With SoC AloneTime frame: From baseline until death due to any cause. Assessed until global cohort DCO of 12 March 2021 (maximum of approximately 45 months).

Locations

175 sites in 19 countries. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Bakersfield, California

  • Research Site

    Santa Monica, California

  • Research Site

    Fort Myers, Florida

  • Research Site

    Jacksonville, Florida

  • Research Site

    St. Petersburg, Florida

  • Research Site

    West Palm Beach, Florida

  • Research Site

    Louisville, Kentucky

  • Research Site

    Kansas City, Missouri

  • Research Site

    Canton, Ohio

  • Research Site

    Pittsburgh, Pennsylvania

  • Research Site

    Chattanooga, Tennessee

  • Research Site

    Nashville, Tennessee

  • Research Site

    Fort Worth, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Richmond, Virginia

  • Research Site

    Barretos, Brazil

  • Research Site

    Belo Horizonte, Brazil

  • Research Site

    Curitiba, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    Ribeirão Preto, Brazil

  • Research Site

    Rio de Janeiro, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    Santo André, Brazil

  • Research Site

    São José do Rio Preto, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Beijing, China

  • Research Site

    Beijing, China

  • Research Site

    Changchun, China

Showing 40 of 175 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.